Protocol M

Type:
Incidence / prospective cohort
Study Status:
Completed
Enrollment Status:
Closed
Countries:
Kenya
Partners:
Kenya AIDS Vaccine Initiative-Kangemi (KAVI-Kangemi), Nairobi, Kenya; Kenya AIDS Vaccine Initiative-Kenyatta National Hospital (KAVI-KNH), Nairobi, Kenya

Study Summary:
To assess vaccine-induced mucosal HIV-1-specific immune responses in volunteers concurrently enrolled in HIV preventive vaccine trials

Secondary Objectives:
To determine volunteers’ acceptance of mucosal sampling methodsTo help establish the reproducibility and validity of methods of assessing vaccine-induced mucosal HIV-1-specific immune responses.
To compare vaccine-induced systemic HIV-1-specific immune responses with HIV-1-specific immune responses at mucosal surfaces

Protocol D - seasonal

Type:
Incidence / prospective cohort
Study Status:
Completed
Enrollment Status:
Closed
Countries:
Rwanda;Zambia;Uganda
Partners:
Projet San Francisco (PSF-Kigali)-Kigali, Rwanda; Zambia-Emory Research Project (ZEHRP)-Lusaka, Zambia; Medical Research Council (MRC-Masaka)-Masaka, Uganda.

Study Summary:
To establish clinical laboratory reference ranges among adults to determine relevant inclusion and exclusion criteria and to interpret safety data for HIV vaccine trials in the context of medical conditions present in an asymptomatic adult population at multiple sites in Africa and to characterize how these ranges may vary with seasonality

PROTOCOL J

Type:
Incidence / prospective cohort
Study Status:
Ongoing
Enrollment Status:
Open
Countries:
Kenya
Partners:
Kenya AIDS Vaccine Initiative-Kenyatta National Hospital (KAVI-KNH), Nairobi, Kenya; Kenya Medical Research Institute-Centre for Geographic Medicine Research-Coast (KEMRI-CGMRC), Kilifi, Kenya.

Study Summary:
To identify exposed seronegative (ESN) volunteers, defined as individuals who remain HIV seronegative despite repeated exposure to HIV, and characterize the immunologic markers of exposure.

Protocol L

Study Status:
Ongoing
Enrollment Status:
Varies across multiple sites
Countries:
Kenya;Uganda;Rwanda;United Kingdom;Zambia
Partners:
Kenyatta National Hospital-KAVI (Kenya) Kangemi-KAVI (Kenya) Entebbe-MRC (Uganda) Kigali-PSF (Rwanda) Lusaka-ZEHRP (Zambia) Entebbe-UVRI/ IAVI (Uganda) London-St Mary’s (UK)

Protocol C

Type:
Natural history / prespective cohort
Study Status:
Ongoing
Enrollment Status:
Open
Countries:
Kenya;Uganda;Rwanda;Zambia;South Africa
Partners:
Kenya AIDS Vaccine Initiative-Kangemi (KAVI-Kangemi), Nairobi, Kenya; Kenya AIDS Vaccine Initiative-Kenyatta National Hospital (KAVI-KNH), Nairobi, Kenya; Kenya Medical Research Institute-Centre for Geographic Medicine Research-Coast (KEMRI-CGMRC), Kilifi, Kenya; Medical Research Council (MRC-Entebbe)-Entebbe, Uganda; Medical Research Council (MRC-Masaka)-Masaka, Uganda; Uganda Virus Research Institute-International AIDS Vaccine Initiative (UVRI-IAVI)-Entebbe, Uganda; Projet San Francisco (PSF-Kigali)-Kigali, Rwanda; Zambia-Emory Research Project (ZEHRP)-Copperbelt, Kitwe, Zambia; Zambia-Emory Research Project (ZEHRP)-Copperbelt-Ndola, Zambia; Zambia-Emory Research Project (ZEHRP)-Lusaka, Zambia; Aurum Institute, Rustenburg, South Africa; Desmond Tutu HIV Foundation (DTHF), Cape Town, South Africa.

Study Summary:
To evaluate clinical, laboratory, immunologic and viral markers of disease progression in volunteers with recent HIV infection to prepare for activities relevant to the execution of preventive HIV vaccine efficacy trials. If identifiable and willing, HIV-infected partner(s) of enrolled volunteers will be assessed for virologic and immunogenetic parameters relevant to transmission.